Phase II Study of Single Agent Paclitaxel in Adult Patients with Relapsed Acute Lymphocytic Leukemia

被引：0
|
作者：
Dawn E. Colburn
Deborah A. Thomas
Francis J. Giles
机构：
[1] The University of Texas,Department of Leukemia
[2] M.D. Anderson Cancer Center,undefined
来源：
Investigational New Drugs | 2003年 / 21卷
关键词：
paclitaxel; refractory; acute lymphocytic leukemia; adult;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3–4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.
引用
收藏
页码：109 / 111
页数：2
相关论文
共 50 条
  • [31] Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study
    Doubek, Michael
    Brychtova, Yvona
    Panovska, Anna
    Sebejova, Ludmila
    Stehlikova, Olga
    Chovancova, Jana
    Malcikova, Jitka
    Smardova, Jana
    Plevova, Karla
    Volfova, Pavlina
    Trbusek, Martin
    Mraz, Marek
    Bakesova, Denisa
    Trizuljak, Jakub
    Hadrabova, Marketa
    Obrtlikova, Petra
    Karban, Josef
    Smolej, Lukas
    Oltova, Alexandra
    Jelinkova, Eva
    Pospisilova, Sarka
    Mayer, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (05) : 417 - 421
  • [32] A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaiVe and Relapsed Chronic Lymphocytic Leukemia
    Strati, Paolo
    Thompson, Philip A.
    Keating, Michael
    Hinojosa, Christina
    Rodriguez, Diana
    Wang, Xuemei
    Daver, Naval G.
    Jain, Nitin
    Burger, Jan A.
    Estrov, Zeev
    Wierda, William G.
    Kantarjian, Hagop M.
    Obrien, Susan
    Ferrajoli, Alessandra
    BLOOD, 2016, 128 (22)
  • [33] A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia
    Maraninchi, D
    Vey, N
    Viens, P
    Stoppa, AM
    Archimbaud, E
    Attal, M
    Baume, D
    Bouabdallah, R
    Demeoq, F
    Fleury, J
    Michallet, M
    Olive, D
    Reiffers, J
    Sainty, D
    Tabilio, A
    Tiberghien, P
    Brandely, M
    Hercend, T
    Blaise, D
    LEUKEMIA & LYMPHOMA, 1998, 31 (3-4) : 343 - 349
  • [34] Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia
    Abbi, Kamal K. S.
    Rybka, Witold
    Ehmann, W. Christopher
    Claxton, David F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (01): : 41 - 46
  • [35] A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Abou Dalle, Iman
    Cortes, Jorge E.
    Pinnamaneni, Pramod
    Lamothe, Betty
    Duque, Adolfo Diaz
    Randhawa, Jasleen
    Pemmaraju, Naveen
    Jabbour, Elias
    Ferrajoli, Alessandra
    Wierda, William G.
    Estrov, Zeev
    Konopleva, Marina
    Ravandi, Farhad
    Alvarado, Yesid
    Borthakur, Gautam
    Gandhi, Varsha
    Kantarjian, Hagop M.
    ACTA HAEMATOLOGICA, 2018, 140 (01) : 30 - 39
  • [36] Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia
    Shanafelt, Tait
    Zent, Clive
    Byrd, John
    Erlichman, Charles
    Laplant, Betsy
    Ghosh, Asish
    Call, Timothy
    Villalona-Calero, Miguel
    Jelinek, Diane
    Bowen, Deborah
    Laumann, Kristina
    Wu, Wenting
    Hanson, Curtis
    Kay, Neil
    LEUKEMIA & LYMPHOMA, 2010, 51 (12) : 2222 - 2229
  • [37] Phase I/II Trial of Nanomolecular Liposomal Annamycin in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
    Wetzler, Meir
    Thomas, Debora A.
    Wang, Eunice S.
    Shepard, Robert
    Ford, Laurie A.
    Heffner, Thompson L.
    Parekh, Samir
    Andreeff, Michael
    O'Brien, Susan
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04): : 430 - 434
  • [38] Blinatumomab for Relapsed/Refractory Acute Lymphocytic Leukemia: A Single Center Experience
    Lin, Tara L.
    Mahmoudjafari, Zahra
    Aljitawi, Omar S.
    Singh, Anurag K.
    Shune, Leyla
    Ganguly, Siddhartha
    Abhyankar, Sunil
    McGuirk, Joseph
    BLOOD, 2015, 126 (23)
  • [39] N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
    Kay, Neil E.
    Shanafelt, Tait D.
    Call, Timothy G.
    Wu, Wenting
    Laplant, Betsy R.
    LEUKEMIA & LYMPHOMA, 2009, 50 (04) : 588 - 592
  • [40] Phase II study of marqibo in adult patients with refractory or relapsed philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL)
    O'Brien, S. M.
    Aulitzky, W.
    Ben Yehuda, D.
    Lister, J.
    Schiller, G. J.
    Selter, K.
    Smith, S. E.
    Stock, W.
    Silverman, J. A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345